Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer

World Journal of Surgical Oncology

Volumn 7, Issue , 2009, Pages

  Guardiola, Emmanuel ^a   Delroeux, Delphine ^a   Heyd, Bruno ^a   Combe, Marielle ^b   Lorgis, Veronique ^a   Demarchi, Martin ^a   Stein, Ulrich ^a   Royer, Bernard ^b   Chauffert, Bruno ^c   Pivot, Xavier ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b University Hospital Jean Minjoz ^*  (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ABDOMINAL ABSCESS; ABDOMINAL BLEEDING; ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CARCINOMATOUS PERITONITIS; CHEMOSURGERY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DYSURIA; FEASIBILITY STUDY; HOSPITAL READMISSION; HUMAN; INTESTINE NECROSIS; INTESTINE OBSTRUCTION; KIDNEY DISEASE; KIDNEY FAILURE; LAPAROTOMY; LIVER METASTASIS; LUNG EMBOLISM; LUNG INFECTION; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PERITONITIS; PLEURA EFFUSION; REOPERATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; URINARY TRACT INFECTION; CYSTADENOCARCINOMA; ENDOMETRIOID CARCINOMA; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; METASTASIS; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; PEROPERATIVE CARE; PROGNOSIS; REGIONAL PERFUSION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, ENDOMETRIOID; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CISPLATIN; CYSTADENOCARCINOMA, SEROUS; FEASIBILITY STUDIES; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; INTRAOPERATIVE CARE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

EID: 61349155585     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-7-14     Document Type: Article

References (33)

1. Almadrones LA Treatment advances in ovarian cancer Cancer Nurs 2003, 26:16S-20S. 10.1097/00002820-200312001-00005 15025408
2. Ozols RF Update on the management of ovarian cancer Cancer J 2002, 8(Suppl 1):S22-30. 12075699
3. Carmignani CP Sugarbaker PH Comprehensive approach to advanced primary and recurrent ovarian cancer: A personal experience Expert Rev Anticancer Ther 2004, 4:477-487. 10.1586/14737140.4.3.477 15161446
4. Cannistra SA Cancer of the ovary N Engl J Med 2004, 351:2519-2529. 10.1056/NEJMra041842 15590954
5. Thigpen T The if and when of surgical debulking for ovarian carcinoma N Engl J Med 2004, 351:2544-2546. 10.1056/NEJMe048292 15590959
6. Stuart GC First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer Gynecol Oncol 2003, 90:S8-15. 10.1016/ S0090-8258(03)00472-4 13129490
7. McGuire WP Hoskins WJ Brady MF Kucera PR Partridge EE Look KY Clarke-Pearson DL Davidson M Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 1996, 334:1-6. 10.1056/NEJM199601043340101 7494563
8. Ozols RF Bundy BN Greer BE Fowler JM Clarke-Pearson D Burger RA Mannel RS DeGeest K Hartenbach EM Baergen R Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study J Clin Oncol 2003, 21:3194-3200. 10.1200/JCO.2003.02.153 12860964
9. Markman M Intraperitoneal antineoplastic drug delivery: Rationale and results Lancet Oncol 2003, 4:277-283. 10.1016/S1470-2045(03)01074-X 12732164
10. Rossi CR Mocellin S Pilati P Foletto M Quintieri L Palatini P Lise M Pharmacokinetics of intraperitoneal cisplatin and doxorubicin Surg Oncol Clin N Am 2003, 12:781-794. 10.1016/S1055-3207(03)00030-9 14567031
11. Casper ES Kelsen DP Alcock NW Lewis JL Jr Ip cisplatin in patients with malignant ascites: Pharmacokinetic evaluation and comparison with the iv route Cancer Treat Rep 1983, 67:235-238. 6682012
12. Lopez JA Krikorian JG Reich SD Smyth RD Lee FH Issell BF Clinical pharmacology of intraperitoneal cisplatin Gynecol Oncol 1985, 20:1-9. 10.1016/0090-8258(85)90118-0 4038390
13. Pretorius RG Hacker NF Berek JS Ford LC Hoeschele JD Butler TA Lagasse LD Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma Cancer Treat Rep 1983, 67:1085-1092. 6228294
14. Markman M Rowinsky E Hakes T Reichman B Jones W Lewis JL Jr Rubin S Curtin J Barakat R Phillips M et al Phase I trial of intraperitoneal taxol: A Gynecoloic Oncology Group study J Clin Oncol 1992, 10:1485-1491. 1355523
15. Francis P Rowinsky E Schneider J Hakes T Hoskins W Markman M Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot Study J Clin Oncol 1995, 13:2961-2967. 8523061
16. DeGregorio MW Lum BL Holleran WM Wilbur BJ Sikic BI Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group Cancer Chemother Pharmacol 1986, 18:235-238. 10.1007/BF00273393 3542268
17. Piccart MJ Floquet A Scarfone G Willemse PH Emerich J Vergote I Giurgea L Coens C Awada A Vermorken JB Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 5 a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy Int J Gynecol Cancer 2003, 13(Suppl 2):196-203. 10.1111/j.1525-1438.2003.13360.x 14656280
18. Segna RA Dottino PR Jennings TS Cohen CJ Feasibility of intraoperative administration of chemotherapy for gynecologic malignancies: Assessment of acute postoperative morbidity Gynecol Oncol 1993, 48:227-231. 10.1006/ gyno.1993.1038 8428695
19. Ahmad SA Kim J Sussman JJ Soldano DA Pennington LJ James LE Lowy AM Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion Ann Surg Oncol 2004, 11:387-392. 10.1245/ ASO.2004.09.007 15070598
20. Royer B Guardiola E Polycarpe E Hoizey G Delroeux D Combe M Chaigneau L Samain E Chauffert B Heyd B Kantelip JP Pivot X Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: Influence of protein binding Anticancer Drugs 2005, 16:1009-1016. 10.1097/01.cad.0000176505.94175.d4 16162978
21. Royer B Delroeux D Guardiola E Combe M Hoizey G Montange D Kantelip JP Chauffert B Heyd B Pivot X Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer Cancer Chemother Pharmacol 2008, 61:415-421. 10.1007/ s00280-007-0484-x 17503047
22. Duvillard C Benoit L Moretto P Beltramo JL Brunet-Lecomte P Correia M Sergent C Chauffert B Epinephrine enhances penetration and anti-cancer activity of local cisplatin on rat sub-cutaneous and peritoneal tumors Int J Cancer 1999, 81:779-784. 10.1002/ (SICI)1097-0215(19990531)81:5<779::AID-IJC19>3.0.CO;2-I 10328233
23. Kaplan EL Meier P Nonparametric estimation from incomplete observations J Am Stat Assoc 1958, 53:457-481. 10.2307/2281868
24. Markman M Walker JL Intraperitoneal chemotherapy of ovarian cancer: A review, with a focus on practical aspects of treatment J Clin Oncol 2006, 24:988-994. 10.1200/JCO.2005.05.2456 16461779
25. Walker JL Armstrong DK Huang HQ Fowler J Webster K Burger RA Clarke-Pearson D Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study Gynecol Oncol 2006, 100:27-32. 10.1016/j.ygyno.2005.11.013 16368440
26. Alberts DS Liu PY Hannigan EV O'Toole R Williams SD Young JA Franklin EW Clarke-Pearson DL Malviya VK DuBeshter B Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N Engl J Med 1996, 335:1950-1955. 10.1056/NEJM199612263352603 8960474
27. Markman M Bundy BN Alberts DS Fowler JM Clark-Pearson DL Carson LF Wadler S Sickel J Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J Clin Oncol 2001, 19:1001-1007. 11181662
28. Armstrong DK Bundy B Wenzel L Huang HQ Baergen R Lele S Copeland LJ Walker JL Burger RA Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 2006, 354:34-43. 10.1056/NEJMoa052985 16394300
29. Markman M Intraperitoneal chemotherapy as treatment of ovarian carcinoma: Why, how, and when? Obstet Gynecol Surv 1987, 42:533-539. 10.1097/00006254-198709000-00001 3309746
30. ten Bokkel Huinink WW Dubbelman R Aartsen E Franklin H McVie JG Experimental and clinical results with intraperitoneal cisplatin Semin Oncol 1985, 12:43-46. 4048975
31. Dedrick RL Myers CE Bungay PM DeVita VT Jr Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer Cancer Treat Rep 1978, 62:1-11. 626987
32. Look M Chang D Sugarbaker PH Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum Int J Gynecol Cancer 2004, 14:35-41. 10.1111/j.1048-891x.2004.14008.x 14764027
33. Topuz E Eralp Y Saglam S Saip P Aydiner A Berkman S Yavuz E Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer. Consolidative intraperitoneal cisplatin in ovarian cancer Gynecol Oncol 2004, 92:147-151. 10.1016/ j.ygyno.2003.10.002 14751150